Pelthos Therapeutics Inc. (PTHS) Stock Price & Analysis
Pelthos Therapeutics Inc. (PTHS) closed at USD 20.26 on Thursday, October 15, 2026, up 0.05% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 20.25; the Oct 15, 2026 session ranged USD 20.15–20.81 on volume of 59,918 shares. Market capitalization is $77.56M, with a 52-week range of USD 18.19–37.5 (ASE). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PTHS.md
Key facts (PTHS)
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 51.71 (range 40–64).
- Total return with dividends: 1Y -28.9% vs S&P 500 +18.1%; 5Y -57.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -3.06, revenue estimate $17.6M.
Analysts (PTHS)
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 51.71 (low 40, high 64).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Lake Street | Target lowered | Buy | $50 → $40 |
| 2026-08-14 | Oppenheimer | Target lowered | Outperform | $66 → $64 |
Total return (dividends reinvested) (PTHS)
| 1Y (from 2025-10-16) | 5Y (from 2024-02-12) | |
|---|---|---|
| Total return | -28.9% | -57.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -29.0% | -27.6% |
| Volatility (annualized) | 75.0% | 113.6% |
| Max drawdown | -51.4% (Nov 2025→Feb 2026) | -88.2% (Feb 2024→Oct 2024) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 20.26 |
|---|---|
| Change | ▲ 0.05% (up) |
| Previous Close | USD 20.25 |
| Open | USD 20.43 |
| Day Range | USD 20.15 – 20.81 |
| 52-Week Range | USD 18.19 – 37.5 |
| Volume | 59,918 shares |
| Market Cap | $77.56M |
| Exchange | ASE |
Technical Analysis (PTHS)
Nexqual's technical model rates PTHS "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.61 (neutral) |
| vs SMA50 | Below (USD 23.71) |
| MACD | -0.94 (negative) |
Analyst Ratings (PTHS)
Wall Street analysts rate PTHS "Buy" based on 7 analysts, with a mean price target of USD 51.71 (range USD 40–64), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 51.71 |
| High Target | USD 64 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (PTHS)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -3.06 |
| Revenue Estimate | $17.59M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -3.79 vs est -2.95 ▼ miss |
| 2026-03-31 | USD -4.66 vs est -3.58 ▼ miss |
| 2025-12-31 | USD -2.69 vs est -4.19 ▲ beat |
| 2025-09-30 | USD -5.3 vs est -0.58 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (PTHS)
| Total Revenue | $43.30M |
|---|---|
| Gross Margin | +75.58% |
| Operating Margin | -101.41% |
| Profit Margin | -199.50% |
| Current Ratio | 1.98 |
| Total Cash | $24.19M |
| Total Debt | $73.11M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (PTHS)
Nexqual rates Pelthos Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $24M cash vs $73M debt |
| Cash Flow | Weak — Operating cash flow -$42M (TTM) |
| Efficiency | Mixed — No data |
Ownership (PTHS)
| Insider Ownership | +50.05% |
|---|---|
| Institutional Ownership | +42.26% |
| Shares Outstanding | 3.83M |
| Float | 1.36M |
| Short % of Float | +5.06% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (PTHS)
Pelthos Therapeutics Inc. is led by Scott M. Plesha (age 60), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO, President & Director | Scott M. Plesha (age 60) |
|---|---|
| CFO, Treasurer & Secretary | John M. Gay (age 49) |
Major Backers & Investors (PTHS)
Notable institutional backers of Pelthos Therapeutics Inc. include AIGH Capital Management LLC, Murchinson Ltd., Ikarian Capital, LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 8.6% |
| Murchinson Ltd. | 7.95% |
| Ikarian Capital, LLC | 6.7% |
| Boothbay Fund Management, LLC | 2.66% |
| Cantor Fitzgerald, L.P. | 1% |
| J. Goldman & Co., L.P. | 0.99% |
| Diadema Partners LP | 0.65% |
| Knott David M., Jr. | 0.58% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.08% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt